Clinical Trials Logo

Ph+ ALL clinical trials

View clinical trials related to Ph+ ALL.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06051409 Recruiting - Ph+ ALL Clinical Trials

A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ALL.

Start date: August 31, 2023
Phase: Phase 3
Study type: Interventional

A global multicenter, open-label, randomized and registrational Phase 3 study to evaluate efficacy and safety of Olverembatinib combined with chemotherapy versus Imatinib combined with chemotherapy in subjects with newly diagnosed Ph+ALL.